Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-angiogenesis

Paul J. Davis, Faith B. Davis, Mary K. Luidens, Hung Yun Lin, Shaker A. Mousa

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Tetraiodothyroacetic acid (tetrac) is a naturally occurring derivative of thyroid hormone, T4. In the absence or presence of L-T4 or L-T3, tetrac has been found to disrupt a number of functions or events that are important to cancer cells via the known thyroid hormone-tetrac receptor on the plasma membrane integrin αvβ3. These functions include regulation of cell division, local stimulation of angiogenesis, chemo-resistance and resistance to radiation. It is desirable to reformulate tetrac as a nanoparticle whose activity is exclusively at the cell surface integrin. Nanotetrac has been designed to limit tetrac to the extracellular space on the basis of the size of the nanoparticle and to provide optimized exposure of the biphenyl structure and acetic acid side chain of its inner ring to the receptor site on αvβ3. Tetrac and its novel nanoparticulate formulation have anti-angiogenesis activity that transcends the inhibition of thyroid hormone-binding at the integrin. Restriction of nanotetrac to the extracellular space has been verified, and nanotetrac has been shown to be up to 10-fold more potent than unmodified tetrac at its integrin target. Nanotetrac formulations have potential applications as inhibitors of tumor-related angiogenesis and of angiogenesis that is unrelated to malignancy, including clinically significant disorders ranging from skin diseases to vascular proliferation in the retina and neovascularization associated with inflammatory states.

Original languageEnglish
Title of host publicationAngiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets
PublisherSpringer Netherlands
Pages107-117
Number of pages11
ISBN (Print)9789400764675, 9400764669, 9789400764668
DOIs
Publication statusPublished - Nov 1 2013

Fingerprint

Integrins
Extracellular Space
Vascular Skin Diseases
Thyroid Hormones
Nanoparticles
Neoplasms
tetraiodothyroacetic acid
Thyroxine
Acetic Acid
Cell Division
Retina
Cell Membrane
Radiation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Davis, P. J., Davis, F. B., Luidens, M. K., Lin, H. Y., & Mousa, S. A. (2013). Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-angiogenesis. In Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets (pp. 107-117). Springer Netherlands. https://doi.org/10.1007/978-94-007-6467-5_10

Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-angiogenesis. / Davis, Paul J.; Davis, Faith B.; Luidens, Mary K.; Lin, Hung Yun; Mousa, Shaker A.

Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets. Springer Netherlands, 2013. p. 107-117.

Research output: Chapter in Book/Report/Conference proceedingChapter

Davis, PJ, Davis, FB, Luidens, MK, Lin, HY & Mousa, SA 2013, Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-angiogenesis. in Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets. Springer Netherlands, pp. 107-117. https://doi.org/10.1007/978-94-007-6467-5_10
Davis PJ, Davis FB, Luidens MK, Lin HY, Mousa SA. Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-angiogenesis. In Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets. Springer Netherlands. 2013. p. 107-117 https://doi.org/10.1007/978-94-007-6467-5_10
Davis, Paul J. ; Davis, Faith B. ; Luidens, Mary K. ; Lin, Hung Yun ; Mousa, Shaker A. / Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-angiogenesis. Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets. Springer Netherlands, 2013. pp. 107-117
@inbook{f00c5a20910f44d7ae1c9cfdcfe56589,
title = "Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-angiogenesis",
abstract = "Tetraiodothyroacetic acid (tetrac) is a naturally occurring derivative of thyroid hormone, T4. In the absence or presence of L-T4 or L-T3, tetrac has been found to disrupt a number of functions or events that are important to cancer cells via the known thyroid hormone-tetrac receptor on the plasma membrane integrin αvβ3. These functions include regulation of cell division, local stimulation of angiogenesis, chemo-resistance and resistance to radiation. It is desirable to reformulate tetrac as a nanoparticle whose activity is exclusively at the cell surface integrin. Nanotetrac has been designed to limit tetrac to the extracellular space on the basis of the size of the nanoparticle and to provide optimized exposure of the biphenyl structure and acetic acid side chain of its inner ring to the receptor site on αvβ3. Tetrac and its novel nanoparticulate formulation have anti-angiogenesis activity that transcends the inhibition of thyroid hormone-binding at the integrin. Restriction of nanotetrac to the extracellular space has been verified, and nanotetrac has been shown to be up to 10-fold more potent than unmodified tetrac at its integrin target. Nanotetrac formulations have potential applications as inhibitors of tumor-related angiogenesis and of angiogenesis that is unrelated to malignancy, including clinically significant disorders ranging from skin diseases to vascular proliferation in the retina and neovascularization associated with inflammatory states.",
author = "Davis, {Paul J.} and Davis, {Faith B.} and Luidens, {Mary K.} and Lin, {Hung Yun} and Mousa, {Shaker A.}",
year = "2013",
month = "11",
day = "1",
doi = "10.1007/978-94-007-6467-5_10",
language = "English",
isbn = "9789400764675",
pages = "107--117",
booktitle = "Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets",
publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-angiogenesis

AU - Davis, Paul J.

AU - Davis, Faith B.

AU - Luidens, Mary K.

AU - Lin, Hung Yun

AU - Mousa, Shaker A.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Tetraiodothyroacetic acid (tetrac) is a naturally occurring derivative of thyroid hormone, T4. In the absence or presence of L-T4 or L-T3, tetrac has been found to disrupt a number of functions or events that are important to cancer cells via the known thyroid hormone-tetrac receptor on the plasma membrane integrin αvβ3. These functions include regulation of cell division, local stimulation of angiogenesis, chemo-resistance and resistance to radiation. It is desirable to reformulate tetrac as a nanoparticle whose activity is exclusively at the cell surface integrin. Nanotetrac has been designed to limit tetrac to the extracellular space on the basis of the size of the nanoparticle and to provide optimized exposure of the biphenyl structure and acetic acid side chain of its inner ring to the receptor site on αvβ3. Tetrac and its novel nanoparticulate formulation have anti-angiogenesis activity that transcends the inhibition of thyroid hormone-binding at the integrin. Restriction of nanotetrac to the extracellular space has been verified, and nanotetrac has been shown to be up to 10-fold more potent than unmodified tetrac at its integrin target. Nanotetrac formulations have potential applications as inhibitors of tumor-related angiogenesis and of angiogenesis that is unrelated to malignancy, including clinically significant disorders ranging from skin diseases to vascular proliferation in the retina and neovascularization associated with inflammatory states.

AB - Tetraiodothyroacetic acid (tetrac) is a naturally occurring derivative of thyroid hormone, T4. In the absence or presence of L-T4 or L-T3, tetrac has been found to disrupt a number of functions or events that are important to cancer cells via the known thyroid hormone-tetrac receptor on the plasma membrane integrin αvβ3. These functions include regulation of cell division, local stimulation of angiogenesis, chemo-resistance and resistance to radiation. It is desirable to reformulate tetrac as a nanoparticle whose activity is exclusively at the cell surface integrin. Nanotetrac has been designed to limit tetrac to the extracellular space on the basis of the size of the nanoparticle and to provide optimized exposure of the biphenyl structure and acetic acid side chain of its inner ring to the receptor site on αvβ3. Tetrac and its novel nanoparticulate formulation have anti-angiogenesis activity that transcends the inhibition of thyroid hormone-binding at the integrin. Restriction of nanotetrac to the extracellular space has been verified, and nanotetrac has been shown to be up to 10-fold more potent than unmodified tetrac at its integrin target. Nanotetrac formulations have potential applications as inhibitors of tumor-related angiogenesis and of angiogenesis that is unrelated to malignancy, including clinically significant disorders ranging from skin diseases to vascular proliferation in the retina and neovascularization associated with inflammatory states.

UR - http://www.scopus.com/inward/record.url?scp=84931452075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931452075&partnerID=8YFLogxK

U2 - 10.1007/978-94-007-6467-5_10

DO - 10.1007/978-94-007-6467-5_10

M3 - Chapter

SN - 9789400764675

SN - 9400764669

SN - 9789400764668

SP - 107

EP - 117

BT - Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets

PB - Springer Netherlands

ER -